Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Aim: To investigate the effectiveness and safety of using chimeric antigen receptor (CAR) T cell therapies targeting CD19 in patients with diffuse large B-cell lymphoma (DLBCL).Methods: PubMed, Embase, and the Cochrane Library were searched for reports published from database inception up to July 20...

Full description

Bibliographic Details
Main Authors: Zhitao Ying, Yuqin Song, Jun Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
chimeric antigen receptor T cells
CD19
diffuse large B-cell lymphoma
clinical efficacy
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.834113/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.834113/full

Similar Items